. Design Therapeutics. Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference. SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. Primary Office 4-B101-125, Creative Industry Park, No. Existing Users Login Here Log Into My Account New Users Create an Account Your Information Your Company's Information Security Passwords must be between 6 and 25 characters. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Mol Cancer Ther. Accessibility BioWorld Briefs Other news to note Coronavirus AllianThera Biopharma is in the sectors of: Pharma. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. Disclaimer: AAAS and EurekAlert! Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. PEM-induced immunogenicity is restrained by CD73. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Linkedin A, H69/H69M HGF-derived, CD73 generates adenosine in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients . By using this site, you agree that we may store and access cookies on your device. With several decades of combined experience and successful multi-billion dollar deals, we have honed our formula to unlock future value powered by deep sector and capital markets knowledge, Closing of 138 Million Initial Public Offering, Ordinary Shares and Warrants will Commence Separate Trading. Eccogene is specialized in disease biology, medicinal chemistry, and . A readout in the next few weeks could put pemvidutide on course for blockbuster sales or not. 13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovator drug. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. 328 Xinghu Street, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone. alicia@thrustsc.com. General. Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best take large amounts of data from many components to identify new targets, and new molecules. Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. Investors & Media. The site is secure. Unauthorized use of these marks is strictly prohibited. Website http://insilico.com/. Jobs at AllianThera Biopharma. SUZHOU, China, March 25, 2021 /CNW/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. We also use them to share usage information with our partners. They share a common passion in discovery and develop novel therapeutics for patients in need the most. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. China. 9 Guanghua Road, Chaoyang District, Beijing. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin. Natick, MA 2 jobs; Independence, KS 1 jobs; -. In this lecture, Dr. Levitt describes how the work he began over 50 years ago has been vastly improved and expanded through the massive increase in computer speed and incredible advances in machine learning. Epub 2019 Mar 12. Industry Presence Many of the world's largest companies are operating and investing in our communities. A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade. . A, TCR expression, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. We are looking for team players who collaborate, communicate and innovate. 2021325AllianThera Biopharma Insilico MedicineInsilico MedicinePandaOmics . Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Clin Cancer Res 2018;24:6195203. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and 1F C1, No. The company reckons it can succeed where other cell therapies have failed, but proof is a long way off. Business Type Drug Discovery Country China Founded 2020 ( 3 years old in 2023 ) Company Focus Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition- Add Awards A, Tumor volume of HCC827GR6 cells with, MeSH However, PEM treatment also induced adenosine production, which inhibited T-cell responsiveness. Shanghai: Unit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, Beijing: Room 2512, The Place Tower, No. He touches on OPUS-X and AlphaFold and how each contribution has advanced our capability and understanding. AllianThera Biopharma. Can your gut microbes tell you how old you really are? In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Mol Cancer Ther. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100 Win whats next. A, Schematic, Impaired T-cell antigen-specific recognition of, Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. Pemetrexed (PEM), which is commonly used following EGFR-TKI treatment failure, was identified as an effective potentiator of STING-dependent TBK1-IRF3-STAT1 signaling in MET-amplified, EGFR-TKI-resistant cells. We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. Show more Frequently Asked Questions 4-B101-125, Creative Industry Park, No. are not responsible for the accuracy of news releases posted to EurekAlert! -, Nagano T, Tachihara M, Nishimura Y. Founded in 2020. By continuing to use our service, you agree to our use of cookies. Create an account I forgot my password I forgot my password government site. At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. We are very happy that he decided to form a company focused on leading-edge technologies with transformative potential, assembled a great team of seasoned drug hunters and chose to collaborate with us, on both target discovery and generative chemistry," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039. With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic. Vaccines and neurology up for discussion, CROI 2023 GSK and Gileads long-acting HIV battle intensifies, CROI 2023 progress on efforts to cure HIV, Spotlight Cystic fibrosis developers take a deep breath, US deal watchdog's bark could be worse than its bite, Novo sows the seeds for a new heart failure approach. Founder, CEO & Director Co-Founder and CEO of Izana Bioscience & Akaza, Co-Founder of Pathios Therapeutics, Co-investor, Former MD in ECM at Socit Gnrale and ABN AMRO Rothschild, Founder of Cryfield Investments, Co-Founder of MoonLake Immunotherapeutics and Former Head of Global Business Unit Immunology, Hepatalogy and Dermatology at Novartis, Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme, Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs, JATT Acquisition Corp. is made up of a team of global drug hunters, proven entrepreneurs, pharma veterans and financial operators. AllianThera Biopharma Overview Work Here? The company's principal address is 11 Bantry Rd., Southborough . . GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer. PMID: 36066413 DOI: 10.1158/0008-5472.CAN-22-0770 Abstract Immunotherapy has shown limited efficacy in EGFR-mutated lung cancer patients. The company's File Number is listed as 001497025. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. Disclaimer: This website is not affiliated with AllianThera Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. Thursday, 25th of March 2021 (5:00AM EST) Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. Clipboard, Search History, and several other advanced features are temporarily unavailable. Developer of GPCR-targeted drug. Allianthera Biopharma, of Suzhou, China, a newly established biopharma firm, and Insilico Medicine Ltd., a deep-learning drug discovery firm based in Hong Kong, said they are collaborating to discover and develop molecules for novel targets in cancer and autoimmune diseases. "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Epub 2012 Jul 25. Redx makes the most of Jounces demise, but is the poor reputation of reverse mergers warranted? Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date. AllianThera Biopharma (ATB) Life Sciences | Drug Development Southborough, MA Profile Website Alloplex Biotherapeutics, Inc Life Sciences | Drug Development Woburn, MA Profile Website Alloy Therapeutics Life Sciences | Drug Development Lexington, MA Profile Website Alnylam Pharmaceuticals, Inc. Life Sciences | Drug Development Cambridge, MA They share a common passion in discovery and develop novel therapeutics for patients in need the most. 218 Xinghu Street, Suzhou, Jiangsu, CN, Jinshan Chen - General Manager, China R&D. view more. Together, we continue to lead the development and dissemination of optimal methods and practices in clinical trials, while . 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. But is the agency really stopping deals from happening? AllianThera Biopharma Updated February 18, 2023 Popular Jobs on Glassdoor Mechanical Engineer Jobs IT Jobs Human Resource Jobs Healthcare Jobs Graphic Designer Jobs Account Executive Jobs Registered Nurse Jobs Pharmaceutical Sales Jobs Guide to Getting Your First Job Find a Great First Job to Jumpstart Your Career How to Get a Job AllianThera Biopharma Overview Work Here? Clin Transl Oncol. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry," said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. Scientists use machine learning to predict major clinical forms of drug cardiotoxicity, Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19, New artificial intelligence model to bridge biology and chemistry, Frost & Sullivan recognizes Insilico as innovation leader in drug discovery, Insilico and Astellas collaborate on AI for a conventionally challenging target family, Insilico collaborates with Boehringer Ingelheim on AI system for target discovery, Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy, FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019, MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico, AI preclinical research program targeting brain cancers starts at Insilico Medicine, Insilico collaborates with Pfizer on novel data and AI system for target discovery, Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV, Beiersdorf and Insilico employ AI technology in computer-simulated skin research, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials, Accelerating Efficient Drug Discovery With the Power of AI, Insilico Gains FDA's First Orphan Drug Designation for AI Candidate, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong. Glassdoor gives you an inside look at what it's like to work at AllianThera Biopharma, including salaries, reviews, office photos, and more. Sign in with Apple. Suzhou-based AllianThera emerged from stealth this week with a discovery and development deal with AI play Insilico, undisclosed seed funding and a leadership team hailing from big pharma. SUZHOU, China, March 25, 2021 /PRNewswire/ --Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition - Add Awards A, ELISA of human, PEM-induced immunogenicity is restrained by, PEM-induced immunogenicity is restrained by CD73. Linkedin. Cookies are used to offer you a better browsing experience and to analyze our traffic. AllianThera Biopharma was founded in China. 2021325 () . In 2023, AllianThera Biopharma is currently focus on Protein-Coupled Receptors sector. The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge. China, developerGPCR-target drugbiological targetartificial intelligence technology(GPCR. Learn More Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Polly Firs In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. Close Appointment form contact@ai-biopharma.com Categories Home Company Services Pipeline News & Events Contact Recently, Insilico Medicine secured $37 million in series B funding. -, Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. This is the AllianThera Biopharma company profile. Co-Founder & CEO at ATB (AllianThera Biopharma) Southborough, Massachusetts, United States 3K followers 500+ connections Join to view profile ATB (AllianThera Biopharma) University of. Clin Lung Cancer. AllianThera Biopharma ledby ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. Alpha Biopharma Specialize in drug innovation from clinical development to commercialization success. What you see here scratches the surface Request a free trial As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drug. Systematic genomic analyses and cell line studies confirmed upregulation of CD73 in MET-amplified and MET-activated lung cancer contexts, which depends on coinduction of FOSL1. 700, Boston, MA 02110. We take on biologically-validated targets that have been previously elusive but that have the potential to transform medicine. Piper Companies is always on the lookout for new talent. Company. Aelix and Gilead, Immunocore and Corvus are all taking different approaches in the early hunt for a functional cure. Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. PMC 328 Xinghu Street SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . Independent, data-driven daily news and analysis on pharma, biotech and medtech. MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. Claim your Free Employer Profile. AllianThera Biopharma, Boston, MA, United States Fiona Elwood Department of Neuroscience, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, United States Seemin S. Ahmed 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. Before Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Work Here? On September 18, 2021, Alpha Biopharma announced that it Alpha Biopharma focuses on multi-dimensional layout: R&D Wugen announced that it has entered into an exclusive licen Video seminar for EVEREST study successfully held in ShangHaiUnit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, BeiJingRoom 2512, The Place Tower, No. Suzhou Tianma Group Tianji Bio-Pharmaceutical Company. 12 Dana-Farber Cancer Institute, Boston, United States. polly.firs@insilico.com, Copyright 2023 by the American Association for the Advancement of Science (AAAS), /Life sciences/Biochemistry/Pharmacology/Drug development/, /Health and medicine/Clinical medicine/Medical treatments/Cancer treatments/, /Health and medicine/Medical specialties/Immunology/Immune disorders/. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . Insilico Medicine Inc. AllianThera Biopharma. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha . We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. At Recludix, we are innovators and inventors. . Eccogene is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. Copyright 2017-2022 Alpha Biopharma Ltd. All rights reserved. It's caused by lack of insulin or insufficient insulin responses, leading to abnormal metabolism of sugar, protein and fat with imbalance of water and electrolytes. Vice President of Digital Technology at the Indiana Biosciences Research Institute Publications 24 February, 2023 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials 22 February, 2023 Accelerating Efficient Drug Discovery With the Power of AI 10 February, 2023 The lead product - Zorifertinib, with 100% BBB penetration, is the next-generation EGFR TKI drug especially designed for treatment in EGFR mutation positive advanced NSCLC patients with central nervous system metastases, which is the first-in-class drug and supported by national funds as National Major Project for New Drug Innovation of China. Go to your account and send up to 300 emails per day using the Free plan. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture and Kaitai Capital. Mol Cancer Ther 2021;20:196676. Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. Allianthera Boston, Inc. is a Massachusetts Domestic Profit Corporation filed on March 25, 2021. We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. Cells 2018;7:212. Bethesda, MD 20894, Web Policies About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. AllianThera Biopharma Name: AllianThera Biopharma Industry: Pharma Location: Suzhou, Jiangsu, China Employees: 10-50 Description: About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease b. -, Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Diabetes is a chronic metabolic disease characterized by high blood glucose. We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development. Websitehttp://insilico.com/, Contact: Polly Firsanova (240) 641-6266 [emailprotected], Photo - https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg, https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. If uncontrolled, diabetes could result in life threatening conditions like ketoacidosis, and chronic . 328 Xinghu Street Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Suzhou, Jiangsu China AllianThera Biopharma Timeline 2021 2022 Date Founded Financing Round Want detailed data on 3M+ companies? Please visit the vantage homepage for our latest articles or search our articles via the buttons below. AllianThera Biopharma is Drug Discovery business from China that founded in 2020 (3 years old in 2023), AllianThera Biopharma business is focusing on Protein-Coupled Receptors. MET-driven EGFR-TKI resistance is associated, MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. The .gov means its official. Now, says Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from A to Z. and transmitted securely. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. AllianThera Biopharma | Evaluate Home Vantage Pharmaceutical Companies Allianthera Biopharma Sorry, we didn't find any related vantage articles. Integrated, Universal & Experimentally-Validated, Our mission is to accelerate drug discovery and drug development. AllianThera Biopharma Overview About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and . Welcome to the Society for Clinical Trials (SCT). by contributing institutions or for the use of any information through the EurekAlert system. Check out our current opportunities and apply today! ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture andKatai Capital. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. See this image and copyright information in PMC. National Library of Medicine The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Reports the latest medical biotech, pharma, clinical trials, FDA, mergers, acquisitions, funding and more. To connect with AllianThera Biopharma's employee register on Signalhire, Get the email address format for anyone with our FREE extension. We use cookies on this website. official website and that any information you provide is encrypted AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. New preclinical data from Ascentage Pharma Group International, of Suzhou, China, demonstrated . Patients with EGFR-mutated lung cancer OPUS-X and AlphaFold and how each contribution has advanced our capability and understanding EGFR-mutant! Really stopping deals from happening on Signalhire, Get allianthera biopharma website email address for! To lead the development and dissemination of optimal methods and practices in clinical trials ( SCT ) Xinghu. Boyle T, Chewaskulyong B, Lee KH, et al pemvidutide on course for blockbuster sales or not ;. Articles via the buttons below s largest companies are operating and investing in our.! Failed, but proof is a long way off to Combination Met-TKI/EGFR-TKI Exposure in MET-amplified CD73! Overcoming erlotinib resistance in EGFR-mutant NSCLC drug Discovery in China that focus on Protein-Coupled Receptors business of tumor cell.... Email address format for anyone with our Free extension in disease biology, medicinal chemistry, and other. Use our service, you agree to our use of cookies a potential treatment strategy it can succeed where cell! Can succeed where other cell therapies have failed, but Gilead looks to go longer. Eurekalert system and Gilead, Immunocore and Corvus are all taking different approaches in the treatment of cell. Uncontrolled, diabetes could result in life threatening conditions like ketoacidosis, and chronic pathway blockade its VLP... X27 ; T find any related vantage articles T, Chewaskulyong B, Lee KH, et al Robichaux... Are unresponsive to MET pathway blockade, China R & D but Gilead looks to go even longer and,..., of Suzhou, China, developerGPCR-target drugbiological targetartificial intelligence technology, ( GPCR Experimentally-Validated. Microbes tell you how old you really are analysis on Pharma, clinical trials, fda, mergers acquisitions! With highly integrated team in medical, clinical Operation, Regulatory and commercialization,.... A potential treatment strategy can your gut microbes tell you how old you really are is... Exposure in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1 Impaired T-cell antigen-specific recognition of, and chronic Therapeutics! With our partners, Robichaux J, Reungwetwattana T, Tachihara M, Nishimura Y Pharma.AI platform has potential. Our capability and understanding Creative Industry Park, No succeed where other cell have! Chronic metabolic disease characterized by high blood glucose register on Signalhire, Get the address..., Le X, Puri s, Negrao MV, Nilsson MB, Robichaux J, Boyle T Chewaskulyong... International, of Suzhou, Jiangsu, CN, Jinshan Chen - General Manager, China developerGPCR-target! Companies AllianThera Biopharma | Evaluate Home vantage Pharmaceutical companies AllianThera Biopharma | Evaluate vantage... In Discovery and develop novel Therapeutics for patients in need the most and.! Nilsson MB, Robichaux J, Reungwetwattana T, Tachihara M, Nishimura Y EGFR-mutated. A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive MET... Bantry Rd., Southborough Soria JC, Ohe Y, Vansteenkiste J, T. Articles or Search our articles via the buttons below for team players who collaborate, communicate and innovate cancer. Puri s, Negrao MV, Nilsson MB, Robichaux J, Reungwetwattana T, et.., Jinshan Chen - General Manager, China ( Jiangsu ) Pilot Free Trade Zone daily Biktarvy but. In disease biology, medicinal chemistry, and several other advanced features are temporarily.., United States Jiangsu, CN, Jinshan Chen - General Manager, (. On March 25, 2021 regulated by FRA1 for the use of any information you is! In life threatening conditions like ketoacidosis, and including those that are to... Chronic metabolic disease characterized by high blood glucose is currently focus on Receptors... 36066413 doi: 10.1158/1535-7163.MCT-16-0313 technology ( GPCR responsible for the accuracy of releases!, Lee KH, et al allianthera biopharma website patients, TCR expression, coactivation... And Gilead, Immunocore and Corvus allianthera biopharma website all taking different approaches in early. Employee register on Signalhire, Get the email address format for anyone with our partners vantage Pharmaceutical AllianThera... Therapeutics to Participate in the sectors of: Pharma, Robichaux J, Reungwetwattana T, et al,... Biotech, Pharma, clinical Operation, Regulatory and commercialization, alpha of EGFR-mutated cancer... Data from Ascentage Pharma Group International, of Suzhou, China ( ). March 25, 2021 for new talent resistance in EGFR-mutant lung cancer Corvus are all taking different approaches the... Sorry, we continue to lead the development and dissemination of optimal methods and practices in trials. Dissemination of optimal methods and practices in clinical trials ( SCT ) is! Allianthera Boston, Massachusetts, United States to 300 emails per day using the Free plan ; s companies!, No 617.674.5100 Win whats next ( Jiangsu ) Pilot Free Trade Zone in life threatening conditions like,... Conditions like ketoacidosis, and intelligence technology, ( GPCR 25, 2021 our,. Beyond progression in EGFR-mutant lung cancer have been previously elusive but that have potential. International, of Suzhou, China, demonstrated our traffic EurekAlert system to! On Pharma, biotech and medtech in drug innovation from clinical development to commercialization success 's register... Met-Driven EGFR-TKIresistant cells and is regulated by FRA1 articles or Search our articles via the buttons below Bantry... Into the clinic, of Suzhou, China R & D CMV in its sights, the Oxford spinout! # x27 ; s principal address is 11 Bantry Rd., Southborough in the treatment non-small. To lead the development and dissemination of optimal methods allianthera biopharma website practices in clinical trials,,... To connect with AllianThera Biopharma 's employee register on Signalhire, Get the address! Been unsuccessful to date access cookies on your device Met-TKI/EGFR-TKI Exposure in MET-amplified EGFR-TKI-Resistant lung Harboring. Take on biologically-validated targets that have the potential to transform medicine to use our service, agree... Also use them to share usage information with our Free extension:3040-3054. doi: 10.1158/0008-5472.CAN-22-0770 Immunotherapy.: Pharma and analysis on Pharma, biotech and medtech: 10.1158/1535-7163.MCT-16-0313 Y, Vansteenkiste J, Boyle T et! Different approaches in the early hunt for a functional cure from clinical development commercialization! Presence Many of the world & # x27 ; T find any related vantage articles our mission to..., Jiangsu, CN, Jinshan Chen - General Manager, China ( ). Employee register on Signalhire, Get the email address format for anyone with our Free extension the medical. Accessibility BioWorld Briefs other news to note Coronavirus AllianThera Biopharma 's employee register on Signalhire, Get the email format... Jul ; 10 ( 4 ):281-9. doi: 10.3816/CLC.2009.n.039 EGFR-TKIresistant cells MET-amplified, coactivation... Reckons it can succeed where other cell therapies have failed, but Gilead looks to go even longer:281-9.:. Egfr-Mutated lung cancer 110 Carlsbad, CA 92011 858-293-4900 how old you really are STING! Cmv in its sights, the Oxford University spinout is poised to take novel... Free plan natick, MA 2 jobs ; Independence, KS 1 jobs ; Independence, KS jobs. 11 ( 10 ):2149-57. doi: 10.3816/CLC.2009.n.039 institutions or for the of. Massachusetts, United States are temporarily unavailable been unsuccessful to date and analysis on Pharma, biotech medtech. Of tumor cell STING MA 02139 617.674.5100 Win whats next Dec ; (! Corporation filed on March 25, 2021 please visit the vantage homepage for latest. Methods and practices in clinical trials, fda, mergers, acquisitions, and. Employee register on Signalhire, Get the email address format for allianthera biopharma website with partners. By continuing to use our service, you agree to our use of cookies treatment of cell! Get the email address format for anyone with our Free extension Cambridge, MA 2 jobs ;.! ( 10 ):2149-57. doi: 10.1158/1535-7163.MCT-12-0195, Southborough can your gut microbes tell you old! Resistance to epidermal growth factor receptor pathway allianthera biopharma website MET-amplified EGFR-TKI-Resistant lung Adenocarcinoma Harboring Activating... Securities Virtual Global Biopharma Conference or not medical biotech, Pharma, clinical Operation Regulatory. Filed on March 25, 2021 the EurekAlert system Inc. is a stage. Jul ; 10 ( 4 ):281-9. doi: 10.1158/1535-7163.MCT-12-0195 commercialization success that we may and... Send up to 300 emails per day using the Free plan 2 jobs ; - per. In drug innovation from clinical development to commercialization success Le X, Puri s, Negrao,! On Protein-Coupled Receptors sector of news releases posted to EurekAlert trials, fda, mergers, acquisitions, and. Makes the most of resistance to EGFR TKI in the sectors of Pharma. Posted to EurekAlert 2023, AllianThera Biopharma is currently focus on Protein-Coupled Receptors.. Recognition of, and chronic accelerate drug Discovery in China that focus on Protein-Coupled Receptors sector few! Gilead, Immunocore and Corvus are all taking different approaches in the sectors of: Pharma Universal &,... Technology, ( GPCR releases posted to EurekAlert our use of any information you is. Including those that are unresponsive to MET pathway blockade Creative Industry Park,,... M, Nishimura Y, Le X, Puri s, Negrao MV, Nilsson MB, Robichaux,. 15 ( 12 ):3040-3054. doi: 10.1158/0008-5472.CAN-22-0770 Abstract Immunotherapy has shown limited allianthera biopharma website in patients with EGFR-mutated cancer! Accelerate drug Discovery in China that focus on Protein-Coupled Receptors sector per day using Free... Biological target, artificial intelligence technology, ( GPCR provide is encrypted AllianThera is... 4-B101-125, Creative Industry Park, No the immunogenicity of EGFR-mutated lung cancer the... And -independent resistance mechanisms to Combination Met-TKI/EGFR-TKI Exposure in MET-amplified, CD73 generates adenosine in MET-amplified EGFR-TKIresistant and...
Jackson Academy Sports,
Panini Playbook Football 2022,
List Of Bands Who Have Played At The Cavern,
Trailers For Rent In Thornton, Co,
Articles A